Barclays PLC raised its position in shares of Catalent, Inc. (NYSE:CTLT – Get Rating) by 35.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 268,897 shares of the company’s stock after buying an additional 70,639 shares during the quarter. Barclays PLC owned 0.15% of Catalent worth $12,103,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the company. Cetera Advisor Networks LLC lifted its position in shares of Catalent by 7.1% in the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock worth $217,000 after purchasing an additional 130 shares in the last quarter. Mackay Shields LLC lifted its position in shares of Catalent by 0.6% in the first quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock worth $2,856,000 after purchasing an additional 149 shares in the last quarter. Texas Permanent School Fund lifted its position in shares of Catalent by 0.8% in the fourth quarter. Texas Permanent School Fund now owns 25,569 shares of the company’s stock worth $1,151,000 after purchasing an additional 212 shares in the last quarter. Global Strategic Investment Solutions LLC lifted its position in shares of Catalent by 3.4% in the fourth quarter. Global Strategic Investment Solutions LLC now owns 6,937 shares of the company’s stock worth $312,000 after purchasing an additional 229 shares in the last quarter. Finally, Czech National Bank lifted its position in shares of Catalent by 1.1% in the fourth quarter. Czech National Bank now owns 21,065 shares of the company’s stock worth $948,000 after purchasing an additional 238 shares in the last quarter. 99.38% of the stock is owned by hedge funds and other institutional investors.
Insider Transactions at Catalent
In other news, SVP Mario Gargiulo sold 678 shares of the firm’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total value of $33,805.08. Following the sale, the senior vice president now owns 5,676 shares in the company, valued at $283,005.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Catalent news, SVP Mario Gargiulo sold 678 shares of Catalent stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the sale, the senior vice president now owns 5,676 shares in the company, valued at $283,005.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Manja Boerman sold 1,446 shares of Catalent stock in a transaction on Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $72,097.56. Following the sale, the insider now owns 14,414 shares in the company, valued at approximately $718,682.04. The disclosure for this sale can be found here. 0.58% of the stock is currently owned by corporate insiders.
Catalent Trading Down 0.5 %
Shares of Catalent stock opened at $38.81 on Friday. The company’s fifty day simple moving average is $44.41 and its 200-day simple moving average is $52.41. The company has a market cap of $6.99 billion, a price-to-earnings ratio of 17.17, a PEG ratio of 5.85 and a beta of 1.18. The company has a current ratio of 1.91, a quick ratio of 1.38 and a debt-to-equity ratio of 0.86. Catalent, Inc. has a 1 year low of $31.45 and a 1 year high of $115.33.
Analyst Upgrades and Downgrades
CTLT has been the subject of a number of research analyst reports. StockNews.com started coverage on shares of Catalent in a research report on Thursday, May 18th. They issued a “sell” rating for the company. Royal Bank of Canada cut their price objective on shares of Catalent from $58.00 to $41.00 in a research report on Monday, May 8th. Barclays cut their price objective on shares of Catalent from $40.00 to $35.00 in a research report on Sunday, May 21st. William Blair lowered shares of Catalent from an “outperform” rating to a “market perform” rating in a research report on Friday, April 14th. Finally, JPMorgan Chase & Co. lowered shares of Catalent from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $90.00 to $45.00 in a research report on Sunday, May 21st. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $67.55.
About Catalent
(Get Rating)
Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
See Also
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLT – Get Rating).
Receive News & Ratings for Catalent Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Catalent and related companies with MarketBeat.com’s FREE daily email newsletter.